Area of research
Endocrinology, Diabetes and Metabolism · Pathology and Forensic Medicine
Research interest
Research interests include Ophthalmology and Eye Disorders, Thyroid Disorders and Treatments, Vestibular and auditory disorders, and Pituitary Gland Disorders and Treatments.
Serum mTOR: an associative marker of Graves' orbitopathy.
Markers of fibrosis in orbital tissues from patients graves' orbitopathy: a retrospective cohort study.
Long-term outcome of Graves' orbitopathy following treatment with sirolimus.
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimus.
Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves' orbitopathy.
In vivo and in vitro evidence for a protective role of autoantibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' orbitopathy.
Role of genetics and epigenetics in Graves' orbitopathy.
IgG4 serum levels in Graves' orbitopathy.
A case of carotid cavernous fistula mimicking Graves' orbitopathy.
Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)
Insights Into the Role of DNA Methylation and Gene Expression in Graves Orbitopathy.
Anti-nuclear autoantibodies in Graves' disease and Graves' orbitopathy.
Absence of a relationship between vitamin D and Graves' orbitopathy.
Autoimmune hepatitis after high-dose intravenous glucocorticoids for Graves' orbitopathy.
Sirolimus as a second-line treatment for Graves' orbitopathy.
Role of the mononuclear cell infiltrate in Graves' orbitopathy (GO): results of a large cohort study.
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy
Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment
Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves' orbitopathy.
Graves' disease and Graves' orbitopathy following COVID-19.
Genetic Profiling of Orbital Fibroblasts from Patients with Graves’ Orbitopathy
Statins: A New Hope on the Horizon of Graves Orbitopathy?
Beneficial effect of low-dose radioiodine ablation for Graves' orbitopathy: results of a retrospective study.
Prediction of heparin binding of mutated short sequences of rat thyroglobulin.
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study
Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis.
Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves' Disease: results of a pilot study.
Occurrence of Graves' hyperthyroidism and Graves' orbitopathy after fine-needle aspiration biopsy of thyroid nodules.
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial